CorInnova, Inc.

JLABS @ TMC

2450 Holcombe Blvd. Suite J

Houston, Texas 77021

Phone: (346) 772-0345

Email: info@corinnova.com

© 2018 CorInnova. All Rights Reserved.

FOLLOW US:

  • LinkedIn Social Icon
  • Twitter Social Icon
Please reload

Heart Failure Treatment Challenge

______

There are an estimated 1,000,000  end stage (Class IV) heart failure patients in the US and EU today, including both systolic and HFpEF heart failure patients.  These patients have a 40% to 50% chance of dying within two years. 

The fundament public health problem for these end stage heart failure patients is that few heart transplants are available for many in need (4,500 per year worldwide) – no other therapy is nearly as effective as a heart transplant – and few patients are eligible for the only device treatment available – left ventricular assist devices, or LVADs,  The adoption of LVADs has been slow (only about 7,200 implanted in 2014) and is limited in the long term because of the limitations of the highly invasive implantation required and the high rate of significant adverse events associated with the device's contact with the blood. 

Even with an estimated 12% rate of growth in LVAD usage, only about 1.8% of these 1,000,000 end stage patients will be treated by LVADs by 2021, and only 0.45% will receive heart transplants, leave 98% needing a device alternative, as noted in the chart below.  CorInnova’s less invasive technology may be able to treat many of the patients who are not able to use LVADs, estimated to be up to 280,000 patients or more.

There are an estimated 1,000,000  end stage (Class IV) heart failure patients in the US and EU today, including both systolic and HFpEF heart failure patients.  These patients have a 40% to 50% chance of dying within two years. 

The fundament public health problem for these end stage heart failure patients is that few heart transplants are available for many in need (4,500 per year worldwide) – no other therapy is nearly as effective as a heart transplant – and few patients are eligible for the only device treatment available – left ventricular assist devices, or LVADs,  The adoption of LVADs has been slow (only about 7,200 implanted in 2014) and is limited in the long term because of the limitations of the highly invasive implantation required and the high rate of significant adverse events associated with the device's contact with the blood. 

Even with an estimated 12% rate of growth in LVAD usage, only about 1.8% of these 1,000,000 end stage patients will be treated by LVADs by 2021, and only 0.45% will receive heart transplants, leave 98% needing a device alternative, as noted in the chart below.  CorInnova’s less invasive technology may be able to treat many of the patients who are not able to use LVADs, estimated to be up to 280,000 patients or more.

 

Below are a chart and photograph illustrating the invasive attachment of an LVAD (cost - roughly $100,000).  Open chest surgery is mostly required, taking 6 to 8 hours or longer, and recovery times are long – 20 to 35 days.


LVAD Usage is further limited by the complications associated with blood contact, as noted in the chart below.  The rate of stroke, the most serious complication, is unchanged from the 10% range reported in the REMATCH trial in 2001, even after 16 years of improved technology, such as the development of continuous flow and ever-smaller LVAD devices.  Overall, overcoming stroke and other blood contacting complications has proven problematic even after considerable support from the NIH for the Artificial Heart Program and approximately $2 billion in development expenditures since 1994 by the three largest LVAD companies (as disclosed in publicly available reports).